Lumos Pharma Inc. | NLNK - Operating Profit

Newlink Genetics reported $-8835000 in Operating Profit for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Operating Profit Change
Bristol Myers Squibb BMY:US USD 1.94B 528M
Capricor Therapeutics CAPR:US USD -8066000 1.59M
Celldex Therapeutics CLDX:US USD -27885000 189K
Eli Lilly And LLY:US USD 1.84B 159.9M
Idera Pharmaceuticals IDRA:US USD -9327000 3.96M
Intrexon XON:US USD -21797000 14.18M
Merk MRK:US USD 3.51B 505M
Nektar Therapeutics NKTR:US USD -52469000 1.83M
Newlink Genetics NLNK:US USD -8835000 1.28M
Pfizer PFE:US USD 5.17B 4.24B
Prothena PRTA:US USD -72000 50.26M
Sarepta Therapeutics SRPT:US USD -109408000 147.39M
Vascular Biogenics VBLT:US USD -9275000 339K
YTE INCY:US USD 70.09M 68.28M